With the broad S&P 500 US stock index (SPX) closing the end of the third quarter up by almost 21% on the year to date, the rise of just over 9% in the NASDQ Biotech Index (NBI) over the same period seemed paltry. The recent protectionist specter of the BIOSECURE Act may have been unrelated to the biotech sector sitting out the last-minute stock market surge. (Also see "BIOSECURE Act: Potential Supply Chain Hits And Pharma’s Path Ahead" - Pink Sheet, 26 September, 2024.)
Stock Watch: Quarter-End Jockeying At Amgen And Regeneron
Skirmishes In More Than One Therapeutic Area In An Action-Packed Week
As broad stock markets finished the third quarter of 2024 on a high, two large biotech companies battled on more than one front. Despite both announcing positive news in the last week of the quarter, neither seemed to be a clear winner over that period.
More from Stock Watch
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
After lowering its full-year earnings guidance just six weeks before the end of 2024, Bayer, by talking up of the prospects for its new drug launches and a major clinical trial result in 2025, might risk damaging its integrity further.
• By
CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.
More from Business
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.